164 related articles for article (PubMed ID: 22159704)
1. [Evaluation of cancer therapy from the perspective of a statutory health insurance].
Rebscher H; Schellhammer S; Kopp T; Scharnetzky E
Urologe A; 2011 Dec; 50(12):1584-90. PubMed ID: 22159704
[TBL] [Abstract][Full Text] [Related]
2. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
3. [Assessment of the value of health-care services--the first step].
Porzsolt F
Med Klin (Munich); 2008 May; 103(5):321-4. PubMed ID: 18484218
[TBL] [Abstract][Full Text] [Related]
4. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
5. Decision making in Germany: is health economic evaluation as a supporting tool a sleeping beauty?
Gerber-Grote A; Sandmann FG; Zhou M; Ten Thoren C; Schwalm A; Weigel C; Balg C; Mensch A; Mostardt S; Seidl A; Lhachimi SK
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):390-6. PubMed ID: 25444297
[TBL] [Abstract][Full Text] [Related]
6. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
7. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacoeconomics in uro-oncology: the concept of QALYs].
Poulsen Nautrup B
Urologe A; 2011 Dec; 50(12):1573-7. PubMed ID: 22159702
[TBL] [Abstract][Full Text] [Related]
9. [Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies].
Ludwig WD; Schildmann J
Onkologie; 2011; 34 Suppl 1():6-10. PubMed ID: 21389762
[TBL] [Abstract][Full Text] [Related]
10. [Decision-analytical modelling of costs per QALY in the context of the German Social Law].
Rogowski WH; Landauer M; John J
Gesundheitswesen; 2009 Nov; 71(11):739-50. PubMed ID: 19551622
[TBL] [Abstract][Full Text] [Related]
11. Analysing the impact of health-care system change in the EU member states--Germany.
Wörz M; Busse R
Health Econ; 2005 Sep; 14(Suppl 1):S133-49. PubMed ID: 16161188
[TBL] [Abstract][Full Text] [Related]
12. [Rationalization, rationing, prioritization: terminology and ethical approaches to the allocation of limited resources in hematology/oncology].
Winkler E
Onkologie; 2011; 34 Suppl 1():2-5. PubMed ID: 21389761
[TBL] [Abstract][Full Text] [Related]
13. The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population.
Tscheulin DK; Drevs F
Eur J Health Econ; 2010 Apr; 11(2):141-50. PubMed ID: 19449159
[TBL] [Abstract][Full Text] [Related]
14. [Cost control in public health by rationing--what are the advantages and disadvantages?].
Mielck A; John J
Gesundheitswesen; 1996 Jan; 58(1):1-9. PubMed ID: 8851125
[TBL] [Abstract][Full Text] [Related]
15. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
16. [Economic limits in oncology].
Hellriegel KP
Z Arztl Fortbild Qualitatssich; 2000 Dec; 94(10):833-6. PubMed ID: 11190919
[TBL] [Abstract][Full Text] [Related]
17. A new approach for assessment of IT programs in health care.
Farcaş DD; Cristea C; Ripanu A; Oprişan M
Stud Health Technol Inform; 1997; 43 Pt B():844-8. PubMed ID: 10179787
[TBL] [Abstract][Full Text] [Related]
18. [Oncology caught between economics and efficiency].
Keil TU
Med Klin (Munich); 2000 Jun; 95 Suppl 1():1. PubMed ID: 10941245
[No Abstract] [Full Text] [Related]
19. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
Schlette S; Hess R
Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
[TBL] [Abstract][Full Text] [Related]
20. [Critical reflections on the prioritisation debate: are we setting the right priorities to address our prioritisation challenges?].
Penner A
Z Evid Fortbild Qual Gesundhwes; 2012; 106(6):397-403. PubMed ID: 22857725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
